{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:31:39Z","timestamp":1782891099760,"version":"3.54.5"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["COV20\/00852"],"award-info":[{"award-number":["COV20\/00852"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of some anti\u2010hypertensive drugs in the current COVID\u201019 pandemic has become controversial. This study investigated possible relationships between anti\u2010hypertensive medications use and COVID\u201019 infection risk in the ambulatory hypertensive population. This is a population\u2010based retrospective cohort study involving 34\u00a0936 hypertensive adults &gt;50\u00a0years in Tarragona (Southern Catalonia, Spain) who were retrospectively followed through pandemic period (from 01\/03\/2020 to 30\/04\/2020). Two data sets including demographic\/clinical characteristics (comorbidities and cardiovascular medications use) and laboratory PCR codes for COVID\u201019 were linked to construct an anonymized research database. Cox regression was used to calculate multivariable hazard ratios (HRs) and estimate the risk of suffering COVID\u201019 infection. Across study period, 205 PCR\u2010confirmed COVID\u201019 cases were observed, which means an overall incidence of 586.8 cases per 100\u00a0000 persons\u2010period. In multivariable analyses, only age (HR: 1.03; 95% CI: 1.02\u20101.05; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) and nursing home residence (HR: 19.60; 95% CI: 13.80\u201027.84; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) appeared significantly associated with increased risk of COVID\u201019. Considering anti\u2010hypertensive drugs, receiving diuretics (HR: 1.22; 95% CI: 0.90\u20101.67; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.205), calcium channel blockers (HR: 1.29; 95%CI: 0.91\u20101.82; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.148), beta\u2010blockers (HR: 0.97; 95% CI: 0.68\u20101.37; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.844), and angiotensin\u2010converting enzyme inhibitors (HR: 0.83; 95% CI: 0.61\u20101.13; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.238) did not significantly alter the risk of PCR\u2010confirmed COVID\u201019, whereas receiving angiotensin II receptor blockers was associated with an almost statistically significant reduction risk (HR: 0.67; 95% CI: 0.44\u20101.01; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.054). In conclusion, our data support that receiving renin\u2010angiotensin\u2010aldosterone system inhibitors does not predispose for suffering COVID\u201019 infection in ambulatory hypertensive people. Conversely, receiving angiotensin II receptor blockers could be related with a reduced risk.<\/jats:p>","DOI":"10.1111\/jch.13948","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T15:53:36Z","timestamp":1595692416000},"page":"1379-1388","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Use of distinct anti\u2010hypertensive drugs and risk for COVID\u201019 among hypertensive people: A population\u2010based cohort study in Southern Catalonia, Spain"],"prefix":"10.1111","volume":"22","author":[{"given":"Angel","family":"Vila\u2010Corcoles","sequence":"first","affiliation":[{"name":"Primary Health Care Service Camp de Tarragona Institut Catala de la Salut Tarragona Spain"},{"name":"Unitat de Suport a la Recerca Tarragona\u2010Reus IDIAP Jordi Gol Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Satue\u2010Gracia","sequence":"additional","affiliation":[{"name":"Primary Health Care Service Camp de Tarragona Institut Catala de la Salut Tarragona Spain"},{"name":"Unitat de Suport a la Recerca Tarragona\u2010Reus IDIAP Jordi Gol Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7015-0018","authenticated-orcid":false,"given":"Olga","family":"Ochoa\u2010Gondar","sequence":"additional","affiliation":[{"name":"Primary Health Care Service Camp de Tarragona Institut Catala de la Salut Tarragona Spain"},{"name":"Unitat de Suport a la Recerca Tarragona\u2010Reus IDIAP Jordi Gol Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Torrente\u2010Fraga","sequence":"additional","affiliation":[{"name":"Department of Information and Communication Technologies DAP Camp de Tarragona Institut Catala de la Salut Tarragona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Gomez\u2010Bertomeu","sequence":"additional","affiliation":[{"name":"Department of Microbiology Hospital Universitari Joan XXIII Institut Catala de la Salut Tarragona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Vila\u2010Rovira","sequence":"additional","affiliation":[{"name":"Unitat de Suport a la Recerca Tarragona\u2010Reus IDIAP Jordi Gol Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Hospital\u2010Guardiola","sequence":"additional","affiliation":[{"name":"Primary Health Care Service Camp de Tarragona Institut Catala de la Salut Tarragona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"de Diego\u2010Cabanes","sequence":"additional","affiliation":[{"name":"Primary Health Care Service Camp de Tarragona Institut Catala de la Salut Tarragona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Bejarano\u2010Romero","sequence":"additional","affiliation":[{"name":"Department of Farmacology DAP Camp de Tarragona Institut Catala de la Salut Tarragona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Rovira\u2010Veciana","sequence":"additional","affiliation":[{"name":"Department of Laboral Medicine ACTIVA Mutua Tarragona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Basora\u2010Gallisa","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari per a la recerca a l'Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization.Coronavirus disease 2019 (COVID\u201019): situation report\u201087 https:\/\/www.who.int\/docs\/default\u2010source\/coronaviruse\/situation\u2010reports\/20200416\u2010sitrep\u201087\u2010covid\u201019.pdf?sfvrsn=9523115a_2(2020 [accessed 10 May 2020]."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.03.017"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5394"},{"key":"e_1_2_10_5_1","first-page":"49","article-title":"Continuing versus suspending angiotensin\u2010converting enzyme inhibitors and angiotensin receptor blockers: impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) [published online ahead of print, 2020 May 13]","author":"Lopes RD","year":"2020","journal-title":"Am Heart J"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002450"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002472"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31030-8"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008975"},{"key":"e_1_2_10_12_1","unstructured":"World Medical Association.WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects. Available at:https:\/\/www.wma.net\/policies\u2010post\/wma\u2010declaration\u2010of\u2010helsinki\u2010ethical\u2010principles\u2010for\u2010medical\u2010research\u2010involving\u2010human\u2010subjects\/. [Accessed May 14 2020]."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-10-25"},{"key":"e_1_2_10_14_1","unstructured":"Generalitat de Catalunya.Sub\u2010direcci\u00f3 General de Vigil\u00e0ncia i Resposta a Emerg\u00e8ncies de Salut P\u00fablica. Procediment d\u2019actuaci\u00f3 enfront de casos d\u2019infecci\u00f3 pel nou coronavirus SARS\u2010CoV\u20102. Available at:https:\/\/canalsalut.gencat.cat\/web\/.content\/_A\u2010Z\/C\/coronavirus\u20102019\u2010ncov\/material\u2010divulgatiu\/procediment\u2010actuacio\u2010coronavirus.pdf[Accessed May 16 2020]."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00821-20"},{"key":"e_1_2_10_16_1","unstructured":"Who Collaborating Centre for Drug Statistics Methodology.ATC\/DDD Index 2020 Available at:https:\/\/www.whocc.no\/atc_ddd_index\/[Accessed May 12 2020]."},{"key":"e_1_2_10_17_1","volume-title":"Applied Survival Analysis. Regression Modeling of Time to Event Data","author":"Hosmer DW","year":"1999"},{"key":"e_1_2_10_18_1","unstructured":"Consumo. Direcci\u00f3n General de Salud P\u00fablica Calidad e innovaci\u00f3n. Centro de Coordinaci\u00f3n de Alertas y Emergencias Sanitarias.Informaci\u00f3n cient\u00edfica\u2010t\u00e9cnica. Enfermedad por coronavirus COVID19. Actualizaci\u00f3n 17 de abril Available at:https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/ccayes\/alertasActual\/nCov\u2010China\/documentos\/20200417_ITCoronavirus.pdf[Accessed May 5 2020]."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02902-w"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.03.017"},{"key":"e_1_2_10_21_1","first-page":"cvaa097","article-title":"Hypertension, the renin\u2013angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID\u201019","author":"Kreutz R","year":"2020","journal-title":"Cardiovasc Res"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.317134"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-0455-8"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.94655"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14871"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2012924"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-020-00144-0"},{"key":"e_1_2_10_28_1","unstructured":"European Society of Cardiology.Position Statement of the ESC Council on Hypertension on ACE\u2010Inhibitors and Angiotensin Receptor Blockers Available at:https:\/\/www.escardio.org\/Councils\/Council\u2010on\u2010Hypertension\u2010(CHT)\/News\/position\u2010statement\u2010of\u2010the\u2010esc\u2010council\u2010on\u2010hypertension\u2010on\u2010ace\u2010inhibitors\u2010and\u2010ang[Accessed May 15 2020]."},{"key":"e_1_2_10_29_1","unstructured":"American Heart Association.HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID\u201019 Available at:https:\/\/professional.heart.org\/professional\/ScienceNews\/UCM_505836_HFSAACCAHA\u2010statement\u2010addresses\u2010concerns\u2010re\u2010using\u2010RAAS\u2010antagonists\u2010in\u2010COVID\u201019.jsp[Accessed May 15 2020]."}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.13948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.13948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jch.13948","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.13948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T19:59:50Z","timestamp":1693943990000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.13948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/jch.13948"],"URL":"https:\/\/doi.org\/10.1111\/jch.13948","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"2020-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}